DesigneRx Pharmaceuticals Inc. is permanently ending manufacturing at its Vacaville site, a move that will eliminate dozens of jobs in stages through mid-November while a small crew remains to support the site wind-down. The company operates a pharmaceutical manufacturing site at 4941 Allison Parkway, Suite B. An Oct. 21 WARN notice associated with the company appears in the state's EDD log.
The closure has been unfolding in phases since summer. As the Press Democrat first reported, DesigneRx notified the state in July that it wanted to end manufacturing at the Allison Parkway address, initially affecting 25 workers whose layoffs were set to begin Sept. 21 and wrap up by mid-October. The company then filed another WARN notice on Sept. 14 covering seven more employees, with those layoffs scheduled for Nov. 15, according to the same report.
Roughly five employees are expected to remain at the 45,000-square-foot building, which Press Democrat reporting notes is leased from the Yeh family, to support the wind-down, decommission the site and eventually turn it over to the landlord.
A Biologics Maker Tied to a Struggling Parent Company
DesigneRx is affiliated with Polaris Group and specializes in research, development and manufacturing of biologics and peptide drugs, according to the company's own description on polarispharma.com. Polaris separately markets the Vacaville site as a contract development and manufacturing organization that performs every step in-house, from cell-bank production through fill and finish, per its CDMO Vacaville page.
The closure comes against a backdrop of financial strain at the parent company. Polaris Group's net loss doubled from the prior year to NT$4.22 billion, or roughly $134.4 million, the Press Democrat reported. The company also announced in May that it was suspending a phase 3 clinical trial of ADI-PEG 20 alongside two other drugs for leiomyosarcoma.
Solano County's Biomanufacturing Ambitions Face Headwinds
Solano County has been described as a potential bioeconomy hub, while Vacaville has discussed plans to develop as a biomanufacturing hub.
That same analysis pointed to a longer-term restructuring trend, noting that leading biomedical companies have been divesting large manufacturing operations in favor of narrower, more competitive pipelines, and it cited Genentech's 2023 Vacaville divestment as an example. Contract development and manufacturing organizations (CDMOs) are also part of the pharmaceutical manufacturing landscape.
Workers Face a Tight Local Job Market
The Workforce Development Board of Solano County is assisting workers affected by the DesigneRx closure, according to the Press Democrat's reporting. But those laid-off employees are entering a labor market the board itself has flagged as strained. In a separate report, the board's executive director said there were about 10,000 unemployed workforce members countywide against roughly 2,500 open roles, or about one job for every four job seekers.
The Vacaville layoffs also fit into a national pattern. Manufacturing nationwide added just 9,000 jobs in September, a 40 percent drop from August, even as manufacturing unemployment fell to 423,000 workers from 571,000 a year earlier, according to Manufacturing Dive. The outlet reported that multiple U.S. manufacturers filed notices about job cuts and closures in September alone, with many of those actions set to unfold through the first half of 2027.
